VenX: First-in-class libraries of virtual and synthetic venoms for drug discovery

• Unité de recherche: INNOSUISSE
• Numéro de projet: 13876.1;10 PFLS-LS
• Titre du projet anglais: VenX: First-in-class libraries of virtual and synthetic venoms for drug discovery

Description succincte (Anglais)

VenX: First-in-class libraries of virtual and synthetic venoms for drug discovery

Description succincte (Français)

VenX: First-in-class libraries of virtual and synthetic venoms for drug discovery

Résumé des résultats (Abstract) (Anglais)

Venoms are a proven source for the discovery of new drugs with high added value, and Atheris, a familyowned company with 18 employees is a world leader in the field. The VenX project develops and combines innovative technology in transcriptomics, bioinformatics and peptide synthesis to overcome the technical challenges that currently limit further growth. Success will generate new products for sale, providing an estimated 20-30% revenue increase for Atheris, and help consolidate its position as a market leader through the set up of new technology platform.

Résumé des résultats (Abstract) (Français)

Venoms are a proven source for the discovery of new drugs with high added value, and Atheris, a familyowned company with 18 employees is a world leader in the field. The VenX project develops and combines innovative technology in transcriptomics, bioinformatics and peptide synthesis to overcome the technical challenges that currently limit further growth. Success will generate new products for sale, providing an estimated 20-30% revenue increase for Atheris, and help consolidate its position as a market leader through the set up of new technology platform.